Form 4: Amylyx Pharmaceuticals' Chief Medical Officer Sells Shares to Cover Tax Obligations
SEC Form 4
Chief Medical Officer of Amylyx Pharmaceuticals, Camille L Bedrosian, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On September 30, 2024, Camille L Bedrosian, the Chief Medical Officer of Amylyx Pharmaceuticals, sold 11,442 shares of common stock.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- The shares were sold at a weighted average price of $3.1952, with individual transactions ranging from $3.125 to $3.24.
- Following the transaction, Bedrosian directly owns 143,801 shares of Amylyx Pharmaceuticals.
- The sale was automatic and not at the discretion of the reporting person.
Sentiment
Score: 5
Explanation: This is a neutral event. The sale of shares to cover tax obligations is a routine transaction and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Form 4 filings are a routine part of the US stock market, and are required by the SEC to ensure transparency when company insiders trade their own company's stock. This filing indicates that the Chief Medical Officer sold shares to cover tax obligations, which is a common practice.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of the transaction (sale of shares) |
| 10/02/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.